Prerpints.org logo
Preprint
Review

Neurotensin and Its Involvement in Female Hormone-Sensitive Cancers

Altmetrics

Downloads

68

Views

44

Comments

0

A peer-reviewed article of this preprint also exists.

Submitted:

25 September 2024

Posted:

26 September 2024

You are already at the latest version

Alerts
Abstract
Neurotensin (NT) is a peptide involved in digestion, neuromodulation, and cancer progression. NT and its receptors (NTR1 and SORT1 mainly) have been widely studied in oncology. Data show NT expression is under the control of sex steroid hormones, in particular estradiol. We focused on its involvement in three main female hormone-sensitive cancers: breast, ovarian, and endometrial cancer in a narrative review. NT, NTR1 and SORT1 are mostly expressed in these three cancers and their involvement in oncologic processes such as proliferation and invasion seems to match, as does their impact on prognosis for most. The development of NT receptor-targeted therapies, including theranostics and radioligand treatments, presents a promising avenue for personalized cancer treatment.
Keywords: 
Subject: Medicine and Pharmacology  -   Oncology and Oncogenics

1. Introduction

Neurotensin (NT) is a 13 amino acid peptide originally isolated from bovine hypothalamus by Carraway and Leeman in 1973 [1]. NT is found both within the central nervous system and in the gastrointestinal tract. On one hand, in the brain, NT has shown different roles such as neuromodulation of dopamine transmission [2] or hypothermia and analgesia [3]. Thus, it has been studied in different pathologies such as schizophrenia [4] and Parkinson’s disease [5]. On the other hand, in the digestive system, it exerts a variety of effects including inhibition of gastric and small bowel motility or facilitation of fatty acid translocation [6]. NT’s role of growth factor of many tissues has been widely studied as well as its involvement in cancer [7].
These different effects are mediated through three receptors. The first NT receptor (NTR1) was cloned in 1990 by Nakanishi et al. who showed it belonged to the family of G-protein-coupled receptors [8]. Similarly, NTR2 also belongs to the G-protein-coupled receptors and has a lower affinity for NT [9]. NTR3 or sortilin (SORT1) is structurally unrelated to the first two and is characterized by a single transmembrane domain [10]. In tumors, NTR1 is considered the main receptor presiding over the effects of NT specifically on cell proliferation, migration and invasion [11]. NTR2 shows a localized distribution, and its expression has been detected in prostate cancer [12]. Unlike NTR1 and NTR2, which are NT-specific, NTR3 binds many other factors and is known to be also involved in tumor progression [13].
NT and its receptors have been widely studied in different neoplastic tissues. Deregulation of the neurotensinergic pathway has been observed in numerous cancers such as colonic adenocarcinoma [14], small-cell lung cancer [15], medullary thyroid carcinoma [16], hepatocellular carcinoma [17], pancreatic cancer [18], breast cancer [19], and non-small cell lung cancer [20]. Here, NT is vastly overexpressed compared with corresponding normal tissues. Aberrant overexpression of NTR1 is also detected in the majority of solid cancers and cancer cell lines, including when it is absent or very weakly expressed in corresponding normal tissues as in breast cancer [19,21], colon cancer [22], pancreatic cancer [18], prostate adenocarcinoma [23], and non-small cell lung cancer [20]. Our team has previously shown that NTR1 expression is linked to the prognosis of hormone-sensitive endometrial and ovarian adenocarcinomas [24,25].
Additionally, research has been done concerning the direct link between sex-steroid hormones especially estrogens, and NT. A high correlation was found between NT, and estrogen receptor (ER) α expression [26,27,28]. Moreover, older and more recent data have shown that NT is expressed and upregulated by estradiol both in the hypothalamus, where it is involved in E2-induced negative feedback mechanisms, and in breast tissue [19,29,30]. Finally, the NT involvement in reproductive functions has been clearly demonstrated [31]. NT participates in an autocrine manner in the mechanisms of ovulation via NTR3; spermatozoa express only its receptors, whereas in the female reproductive system both NT and its receptors are expressed, enhancing the acrosome reaction of spermatozoa in mammals [31].
Since breast, ovarian and endometrial cancers are as the most frequent hormone-sensitive female cancers, we wished to review the data concerning theses three cancers and the involvement of NT, to synthesize what is known concerning the different processes of these cancers and open prognostic and therapeutic perspectives and research avenues for the future.

2. Expression of NT and Its Receptors in Hormone-Sensitive Cancers

2.1. Breast Cancer

The expression of the three different receptors have been assessed in different breast cancer human cell lines.
First, Somaï et al. showed NTR1 over-expression in MCF-7 cells (estrogen receptor (ER) positive cells) via RT-PCR, while it seemed absent in normal epithelial breast cells [32], in accordance with Souazé et al. [21]. NTR1 and NTR2 expressions were confirmed in Western blot in the MCF-7 cells. Using indirect immunofluorescence, NTR2 expression was membranous, unlike NTR1 which was intracytoplasmic and granular, associated with NT pathway activation [33]. NTR1 expression was also detected in MDA-MB-231 (triple negative (TN) cell line) cells with RT-PCR and immunofluorescence assays [34]. Conversely, NTR2 expression was variable across the different breast cancer cell lines; Western blot showed a strong NTR2 expression in ER-positive breast cancer cells, while it was almost absent in TN cancer cells [33]. In a series of 70 patients who underwent tumorectomy or mastectomy for invasive ductal carcinoma (IDC) with concomitant ductal carcinoma in situ (DCIS), 91% were positive for NTR1 with a threshold of 10% stained cells. Among those 70 patients, 50 were then studied and 30% showed a coexpression of NT and NTR1 in immunohistochemistry [21]. Similarly, in the invasive component of 106 samples of IDC studied by Dupouy et al., a majority showed a high proportion of NTR1 positive cells (from 50 to 100%) using immunohistochemistry and even 38 patients (35%) exhibited very high NTR1 expression ( ≥ 80% of tumor cells). Additionally, the subpopulation co-expressing NT and a high expression NTR1 was significantly correlated with positive ER expression [19]. Moreover, NT expression in normal epithelial breast cells is regulated by estradiol as an enhancement of transcripts was observed when those cells were exposed to estradiol and this effect was abolished when exposed to a pure anti-estrogen [19].
SORT1 expression has been well assessed in TN breast cancer cells using Western blot [35,36]. Nevertheless, it was also assessed in different breast cancer cell lines including luminal A (MCF-7) and Human Epidermal Growth Factor Receptor-2 (HER2) positive (SKBR3) cancer cell lines [37]. Similarly, high expressions of SORT1 were not only assessed in TN breast cancer samples [36]. This was confirmed in an immunohistochemistry analysis in a series of 318 clinically annotated breast cancers and 53 adjacent normal tissues showing that most normal tissues presented low levels of SORT1, while the proportion of cases with intermediate or high levels increased in cancers. Indeed, 66% were positive for SORT1 regardless with ER and progesterone receptor (PR) expression or with the different molecular subtypes of breast cancer (luminal A and B, HER2+, TN) [37].

2.2. Ovarian Cancer

NT as well as NTR1 and weak NTR2 expressions were assessed in human ovarian cancer cell lines [25]. In fact, if NT was expressed, in both SKOV3 and A2780 (epithelial ovarian cancer) cell lines, NTR1 mRNA was only detected in SKOV3 cells. Immunohistochemistry studies were then done on 46 ovarian cancer samples assessing a NTR1 positive expression for 72% of them and 74% when it came to NT. By contrast, 10 samples from nonmalignant tissues were analyzed and 9 of them showed a negative or very weak staining.
SORT1 expression was assessed in many ovarian carcinoma cell lines, including SKOV3, using Western blotting. This expression was confirmed using RT-PCR and indirect immunofluorescence staining on ovarian carcinoma samples, while it was either absent or significantly lower in healthy tissues when assessed using various techniques [35,38,39].

2.3. Endometrial Cancer

NT’s presence was assessed in cows [40] and goats endometrium samples where estrogen and progesterone regulate its mRNA levels [41]. NT and NTR1 expression were assessed in human endometrial adenocarcinomas and nonmalignant samples [24]. While 48 benign samples out of 66 were positively labeled with NTR1 antibody with a weak staining in most of them, NTR1 was significantly over-expressed in cancer samples compared to nonmalignant tissues with a global staining nearly 14-fold higher in endometrial adenocarcinomas using immunohistochemistry. Indeed, 90 of the 100 cancer samples were positively labeled with NTR1 antibody with global staining significantly increased with grade. In the same way, all the cancer samples showed a large amount of their cells positively labeled with the anti NT-antibody and thus a significantly higher expression in endometrial adenocarcinomas than in benign samples [24].
Similarly to breast and ovarian cancer, high SORT1 expression was assessed in endometrial cancer cell lines (HEC-1-A, HEC-1-B, AN3-CA, SK-UT-1B and KLE cell lines) using Western blot. Increased SORT1 staining was also seen in endometrial tumors compared to normal endometrial tissues, as 10 out of 12 (83%) samples showed higher expression levels of SORT1 than in healthy tissues [35].
In summary, the expression of NT and its receptors has been thoroughly investigated in hormone-sensitive cancers. In breast cancer, NTR1 and SORT1 appear overexpressed in human samples and in human cancer cells regardless of hormone-sensitive lines. Similarly, ovarian cancer studies reveal variable NTR1 expression between different cell lines and SORT1 expression in many cancer cell lines, with significant overexpression in malignant tissues compared to nonmalignant ones concerning both NTR1 and SORT1 expressions. Likewise, in endometrial cancer, NT, NTR1, and SORT1 appear overexpressed, with NTR1 levels increasing with tumor grade, while their expression are lower or absent in normal tissues. Main data about NT and its receptors expression are summarized in Table 1.

3. Oncologic Processes Involved

The main processes involved in tumor progression via activation of the NT/NTR1 complex are cell proliferation, survival, migration, invasion and neoangiogenesis. NT induces proliferation stimulation in tumor cells from pancreas, colon, prostate and small-cell lung cancer [42,43]. Transcriptome analysis of NT-treated exposed pharyngeal squamous cell carcinoma confirmed the overexpression of genes involved in the metastatic process, such as matrix metalloproteinase (MMP-1) and interleukin IL-8 [44]. Similarly, NT accelerates the migration and invasion colon [45] and pancreatic [46] cancer cells. Finally, NT can promote neoangiogenesis via the urokinase receptor [47], IL-8 and CXCL1 (CXC Motif Chemokine Ligand 1) with simultaneous activation [48].
Similarly, SORT1 is involved in different oncologic processes such as proliferation and migration in hepatocellular carcinoma [49] or pancreatic cancer cell invasion for instance [50]. It was even recently shown to exert a role in vasculogenic mimicry both in ovarian and breast cancer cells [51]. Nonetheless, SORT1 effects are mediated through a variety of different ligands and if its role in NT-mediated oncologic processes in the colon, prostate or pancreas has been well documented [52], the data concerning NT/SORT1 complex in female hormone-sensitive cancer is weak.

3.1. Cell Growth and Proliferation

Proliferation is the most studied process in the literature concerning NT and its receptors. It has been well-documented in both hormone-sensitive and TN breast cancer. For instance, the synthetic NT analogue JMV-449 increased DNA synthesis in MDA-MB-231 cells [53]. In hormone-sensitive breast cancer cells, JMV-449 also stimulated proliferation by inhibiting apoptosis through Bcl-2 proto-oncogene activation, mediated by the MAPK pathway [32]. In xenografted mice with ER-positive tumors, NT overexpression accelerated tumor growth [54]. The NT/NTR1 complex induces overexpression of EGFR, HER2, and HER3. This synergic effect is confirmed with tumor growth restrained by Lapatinib, a tyrosine kinase inhibitor targeting the HER2 and EGFR pathways. Similarly, in TN breast cancer, silencing NTR1 in MDA-MB-231 xenografts resulted in reduced tumor volume and increased tumor doubling time [21]. Comparable results were achieved using SR48692, a specific NTR1 antagonist, further confirming NTR1's role in TN breast tumor growth.
NT also plays a role in ovarian carcinoma proliferation. Exogenous NT treatment increased proliferation in OCAR3, a high-grade serous ovarian carcinoma cell line [55]. SORT1 silencing in Caov-4 cells (another high-grade serous ovarian carcinoma line) led to increased apoptosis and decreased proliferation [39]. Interestingly, a heterodimerization between NTR1 and SORT1, leading to NT internalization, has been described in colonic adenocarcinoma cell lines [56], making NT/NTR1/SORT1 a potential therapeutic target for ovarian carcinoma.

3.2. Invasion and Metastatic Potential

NT and its receptors are involved in tumor invasion and metastasis. In breast cancer, Dupouy et al. demonstrated that ER-positive NT-negative MCF-7 xenografts did not develop metastases, while NT-overexpressing clones developed metastases in 41% and 76% of cases for low and high NT-expressing clones, respectively [54]. Mechanistically, the NT/NTR1 complex promotes pro-metastatic cellular changes by reducing basal cell adhesion, a critical factor for metastatic spread, and synergizes with EGF to enhance cell migration and invasion. In TN breast cancer, NT stimulates invasion and migration through NTR1 activation, leading to matrix metalloproteinase-9 (MMP-9) expression, which is crucial for invasion [21,53]. NTR3 also plays a role in TN cell invasion, as its knockdown in MDA-MB-231 cells inhibited invasion [37].

3.3. Chemo-Resistance

The chemo-resistance was studied in ovarian cancer. In a cohort of 287 high-grade ovarian serous cystadenocarcinoma from The Cancer Genome Atlas (TCGA) database, NTR1 mRNA higher expression was significantly associated with platinum-resistant status (p=0.0076) [25]. NTR1 antagonist improved the responses to platinum salt therapy by inhibiting in vitro cell growth and survival. Using a monoclonal antibody directed against NT on ovarian human cancer cells inoculated in mice, Liu et al. showed that a reduction of NT/NTR1 activation improved the response to platinum salt therapy as it decreased tumor size when cisplatin is combined with NT antibody. It also facilitated nuclear platinum accumulation and reduced carboplatin efflux from the cells [25]. These results are consistent with Han and al. findings, making NT pathway inhibition a promising therapeutic associated with chemotherapy [57].
In summary, NT and its receptors are involved in critical oncologic processes, including proliferation, invasion, metastatic potential, and chemo-resistance. NT promotes tumor proliferation in breast, and ovarian cancers. The NT/NTR1 axis plays a key role in both promoting proliferation and enhancing metastatic potential. Furthermore, NT is involved in chemo-resistance, particularly in ovarian cancer, linking NTR1 expression with platinum-resistant cases. This comprehensive understanding highlights the potential of NT and its receptors as therapeutic targets across multiple cancer types.

4. Clinical Features

4.1. Survival and Prognosis

Few studies encounter for survival data when it comes to NT expression and its receptors in those hormone-sensitive cancers.
To begin with, breast cancers and especially IDC expressing NTR1 were associated to a significantly worse prognosis than those with low receptor expression [19]. Moreover, high NTSR1 expression was linked to a larger tumor size, a grade 3 or the number of positive lymph node, making high NTSR1 expression an independent prognosis marker. NTR3 also seems to be linked to a worse prognosis being associated with lymph node invasion on a cohort of 318 human breast cancer samples [37]. Consistently, high NTR3 expression seems to be associated with a poor prognosis for TN breast cancer, in particular for N+ cancer [36].
Concerning ovarian cancer, a high NTR1 mRNA expression in a cohort of 491 high-grade ovarian serous cystadenocarcinoma from the TCGA database, was linked to a significantly worse prognosis with a shorter progression free survival. Surprisingly, NTR3 expression seemed correlated with a good prognosis [25].
Similarly, NTR1 mRNA high expression level seemed to be linked to a worse overall survival in endometrial cancer. Indeed, statistical analyses of 333 cases form the TGCA cohort of uterine corpus endometrial carcinoma (UCEC) showed a shorter overall survival and progression-free survival both in univariate and multivariate and independently from the histological grade even when including only endometrioid carcinomas. These results were confirmed in a series of 100 consecutive cases of endometrial adenocarcinoma showing that high immunohistochemical expression of NTR1 was significantly correlated with a shorter overall survival (p < 0.001) [24].

4.2. Diagnosis and Pre-Therapeutic

To improve tumor targeting when conventional imaging is insufficient, the neurotensinergic system has potential as a diagnostic tool, particularly studied in prostate and digestive cancers. NT receptors, especially NTR1, have been explored in positron emission tomography (PET) imaging. New nanoparticles labeled with radioisotopes, such as 64Cu-labeled NT analogs, were tested in PC3 (androgen-resistant prostate cancer cell line) cell xenografts and showed promise for identifying NTR-positive lesions with low uptake in normal tissues, which could help predict patient responses to NTR1-targeted therapies [58]. Further studies used 68Ga-labeled peptides functionalized on gold nanoparticles to enhance imaging of hormone-sensitive prostate and colon cancer cells in mice [59]. Similarly, 18F-DEG-VS-NT demonstrated strong tumor uptake in animal models, making NTR1 a promising target, particularly when prostate-specific membrane antigen (PSMA) expression is low [60]. Retrospective autoradiography studies also showed NTR1 positivity in PSMA-negative prostate lesions, reinforcing the potential of NTR1 imaging [61]. Other peptide-based imaging agents targeting NTR1 were successfully tested in xenografted mice with prostate cancer cells [62,63]. In pancreatic cancer, a radiopharmaceutical targeting neurotensin receptors has even been safely tested for the first time in three patients with ductal pancreatic adenocarcinoma [64].
NTR2 has recently emerged as a potential imaging target. A study on an 18F-labeled radioligand showed limited stability in vivo [65], but JMV-7488, a radiometalated NT analog targeting NTR2, demonstrated promising results in estrogen-positive breast cancer and prostate cancer animal models [33].
To address tumor heterogeneity, Ma et al. developed a heterodimer that targets both PSMA and NTR1, which showed prominent uptake in NTR1-positive/PSMA-negative and PSMA-positive/NTR1-negative prostate cancer xenografts [66]. This dual-targeting approach holds promise not only for imaging but also for therapeutic applications, as the heterodimer could be loaded with therapeutic agents.
Theranostics, which combines diagnosis, treatment, and follow-up, is an evolving field. The early success of radiolabeled somatostatin analogs in neuroendocrine tumors has spurred interest in NT receptor-targeting agents for use in multiple cancers [58]. Peptide-based agents may serve as vehicles for delivering radioactivity to cancer cells, offering both diagnostic and therapeutic potential [67]. An exciting example of this approach is the use of Lutetium-177–labeled PSMA (Lu-PSMA), which has shown promise in treating metastatic prostate cancer by delivering targeted radiation to PSMA-expressing tumor cells. Similar strategies could target NT receptors, as demonstrated by Schulz et al., who found that a 177Lu-labeled NTR1-targeting agent effectively delayed tumor growth in NTR1-positive colon carcinoma xenografts, with significant reductions in tumor size [68].

4.3. Other Therapeutic Potentialities

Several NTR agonists and antagonists have been developed for the study of NT binding and activity. Among them, SR48692 (Meclinertant), a selective NTR1 antagonist that has also demonstrated binding to NTR2 and SORT1 at higher concentrations, was well studied. It was shown to reduce cell growth and apoptosis in different ovarian cancer cell lines [55] but also reduced the proliferation of LNCaP prostate cancer cells and of prostate cell lines unresponsive to androgen deprivation therapy [69].
In animal models, daily administration of SR48692 reduced the volume and weight of TN breast cancer xenografts compared to control groups [21]. Additionally, SR48692 combined with carboplatin significantly decreased tumor growth in ovarian adenocarcinoma xenografts [25]. When combined with Enzalutamide, an androgen-receptor inhibitor, SR48692 also reduced neuroendocrine differentiation and slowed tumor growth in prostate cancer xenografts, suggesting that targeting the NT system could delay castration-resistant prostate cancer progression [70]. SR48692 has also demonstrated radiosensitizing effects in PC3 xenografts, reducing tumor burden and enhancing radiation effects in vivo, independent of androgen receptor status [71].
NT-conjugated peptides have been developed to selectively deliver chemotherapeutics into tumor cells [72]. For example, PC3 cell viability was reduced by 70% when methotrexate was conjugated to NT, though free methotrexate had no effect. Similarly, NT-conjugated 5FdU became active in prostate cancer cells. New drug-conjugated NT peptides have been developed, showing cytotoxicity on human prostate cancer cells [73]. Additionally, NT-modified Camptothecin dimeric prodrug nanoparticles have shown enhanced tumor accumulation and reduced systemic toxicity in TN breast cancer models [74].
A peptide requiring SORT1 (TH1902) for internalization was recently tested and showed significant tumor regression in TN breast cancer murine xenografts when conjugated with docetaxel, without major adverse effects [36]. It also showed efficiency in ovarian cancer [75] and thus is even currently teste in a phase 1, open-label first-in-human study in solid cancer (ClinicalTrials.gov; Identifier: NCT04706962).
Chemical antagonists are not the only therapeutic options that may target the NT/NTR complex as new therapeutic drugs appear. Indeed, a monoclonal antibody (LF-NTS mAb) has recently been developed to target NTR1 in metastatic non-small cell lung cancer and lower their aggressiveness. Adding LF-NTS targeted antibody to the standard of care (carboplatin/paclitaxel or Cisplatin/pemetrexed) improved the treatment efficiency and showed to toxicity in mice [76]. The same approach was used in ovarian cancer [25] and is recently studied in TN breast cancer [77].
In summary, most research on therapeutic options targeting NT and its receptors has not focused on female hormone-sensitive cancers. However, recent discoveries regarding the common oncologic processes involving the neurotensinergic pathway suggest that these receptors could become promising therapeutic targets in the future.

5. Conclusion and perspectives

The aim of this review was to synthesize current knowledge on the role of NT and its three receptors in breast, ovarian, and endometrial cancers—three hormone-sensitive cancers (Figure 1). While differences in NT receptor expression exist between these cancers, as well as between their hormone-sensitive and insensitive cell lines, the role of NT and its receptors in oncologic processes, particularly in proliferation and invasion, appears consistent. Additionally, their impact on prognosis seems evident in most cases. Looking forward, the development of NT receptor-targeted therapies, including theranostics and radioligand treatments, presents a promising avenue for personalized cancer treatment. These approaches, such as Lu-NTR1, exemplified by the success of agents like Lu-PSMA, could offer more precise and effective therapeutic options. However, further clinical studies are required to standardize these findings across different cancer types so NT and its receptors can be fully harnessed as diagnostic and therapeutic tools in patient care.

Author Contributions

Conceptualization, M.A. and N.B.; methodology, M.A.; validation, M.A., G.G., and M.B.; investigation, N.B, and M.A.; writing—original draft preparation, N.B.; writing—review and editing, M.A., G.G., and G.R.; M.B., and R.M.; visualization, R.M., and G.R.; supervision, M.A.; project administration, M.A. All authors have read and agreed to the published version of the manuscript.”

Funding

This research received no external funding.

Informed Consent Statement

Not applicable.

Acknowledgements

We thank Dr. Quentin Maury for his kind help in editing the manuscript, and BioRender.com.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Carraway, R.; Leeman, S.E. The isolation of a new hypotensive peptide, neurotensin, from bovine hypothalami. J Biol Chem. 1973, 248, 6854–6861. [Google Scholar] [CrossRef] [PubMed]
  2. Beauregard, M.; Ferron, A.; Descarries, L. Opposite effects of neurotensin on dopamine inhibition in different regions of the rat brain: an iontophoretic study. Neuroscience. 1992, 47, 613–619. [Google Scholar] [CrossRef] [PubMed]
  3. Nemeroff, C.B.; Osbahr AJ 3rd Manberg, P.J.; Ervin, G.N.; Prange, A.J., Jr. Alterations in nociception and body temperature after intracisternal administration of neurotensin, beta-endorphin, other endogenous peptides, and morphine. Proc Natl Acad Sci U S A. 1979, 76, 5368–5371. [Google Scholar] [CrossRef] [PubMed]
  4. Binder, E.B.; Kinkead, B.; Owens, M.J.; Nemeroff, C.B. The role of neurotensin in the pathophysiology of schizophrenia and the mechanism of action of antipsychotic drugs. Biol Psychiatry. 2001, 50, 856–872. [Google Scholar] [CrossRef] [PubMed]
  5. St-Gelais, F.; Jomphe, C.; Trudeau, L.E. The role of neurotensin in central nervous system pathophysiology: what is the evidence? J Psychiatry Neurosci. 2006, 31, 229–245. [Google Scholar]
  6. Thomas, R.P.; Hellmich, M.R.; Townsend, C.M., Jr.; Evers, B.M. Role of gastrointestinal hormones in the proliferation of normal and neoplastic tissues. Endocr Rev. 2003, 24, 571–599. [Google Scholar] [CrossRef]
  7. Carraway, R.E.; Plona, A.M. Involvement of neurotensin in cancer growth: evidence, mechanisms and development of diagnostic tools. Peptides. 2006, 27, 2445–2460. [Google Scholar] [CrossRef]
  8. Tanaka, K.; Masu, M.; Nakanishi, S. Structure and functional expression of the cloned rat neurotensin receptor. Neuron. 1990, 4, 847–854. [Google Scholar] [CrossRef]
  9. Chalon, P.; Vita, N.; Kaghad, M.; Guillemot, M.; Bonnin, J.; Delpech, B.; Le Fur, G.; Ferrara, P.; Caput, D. Molecular cloning of a levocabastine-sensitive neurotensin binding site. FEBS Lett. 1996, 386, 91–94. [Google Scholar] [CrossRef]
  10. Zsürger, N.; Mazella, J.; Vincent, J.P. Solubilization and purification of a high affinity neurotensin receptor from newborn human brain. Brain Res. 1994, 639, 245–252. [Google Scholar] [CrossRef]
  11. Kim, J.T.; Li, J.; Song, J.; Lee, E.Y.; Weiss, H.L.; Townsend, C.M., Jr.; Evers, B.M. Differential expression and tumorigenic function of neurotensin receptor 1 in neuroendocrine tumor cells. Oncotarget. 2015, 6, 26960–26970. [Google Scholar] [CrossRef] [PubMed]
  12. Swift, S.L.; Burns, J.E.; Maitland, N.J. Altered expression of neurotensin receptors is associated with the differentiation state of prostate cancer. Cancer Res. 2010, 70, 347–356. [Google Scholar] [CrossRef] [PubMed]
  13. Nykjaer, A.; Willnow, T.E. Sortilin: a receptor to regulate neuronal viability and function. Trends Neurosci. 2012, 35, 261–270. [Google Scholar] [CrossRef]
  14. Ulich, T.R.; Cheng, L.; Glover, H.; Yang, K.; Lewin, K.J. A colonic adenocarcinoma with argentaffin cells. An immunoperoxidase study demonstrating the presence of numerous neuroendocrine products. Cancer. 1983, 51, 1483–1489. [Google Scholar] [CrossRef] [PubMed]
  15. Moody, T.W.; Carney, D.N.; Korman, L.Y.; Gazdar, A.F.; Minna, J.D. Neurotensin is produced by and secreted from classic small cell lung cancer cells. Life Sci. 1985, 36, 1727–1732. [Google Scholar] [CrossRef] [PubMed]
  16. Baća, I.; Schmidt-Gayk, H. Neurotensin and medullary carcinoma of the thyroid gland. J Cancer Res Clin Oncol. 1981, 100, 229–230. [Google Scholar] [CrossRef]
  17. Ehrenfried, J.A.; Zhou, Z.; Thompson, J.C.; Evers, B.M. Expression of the neurotensin gene in fetal human liver and fibrolamellar carcinoma. Ann Surg. 1994, 220, 484–489. [Google Scholar] [CrossRef]
  18. Wang, J.G.; Li, N.N.; Li, H.N.; Cui, L.; Wang, P. Pancreatic cancer bears overexpression of neurotensin and neurotensin receptor subtype-1 and SR 48692 counteracts neurotensin induced cell proliferation in human pancreatic ductal carcinoma cell line PANC-1. Neuropeptides. 2011, 45, 151–156. [Google Scholar] [CrossRef]
  19. Dupouy, S.; Viardot-Foucault, V.; Alifano, M.; Souazé, F.; Plu-Bureau, G.; Chaouat, M.; Lavaur, A.; Hugol, D.; Gespach, C.; Gompel, A.; Forgez, P. The neurotensin receptor-1 pathway contributes to human ductal breast cancer progression. PLoS One. 2009, 4, e4223. [Google Scholar] [CrossRef]
  20. Alifano, M.; Souazé, F.; Dupouy, S.; Camilleri-Broët, S.; Younes, M.; Ahmed-Zaïd, S.M.; Takahashi, T.; Cancellieri, A.; Damiani, S.; Boaron, M.; Broët, P.; Miller, L.D.; Gespach, C.; Regnard, J.F.; Forgez, P. Neurotensin receptor 1 determines the outcome of non-small cell lung cancer. Clin Cancer Res. 2010, 16, 4401–4410. [Google Scholar] [CrossRef]
  21. Souazé, F.; Dupouy, S.; Viardot-Foucault, V.; Bruyneel, E.; Attoub, S.; Gespach, C.; Gompel, A.; Forgez, P. Expression of neurotensin and NT1 receptor in human breast cancer: a potential role in tumor progression. Cancer Res. 2006, 66, 6243–6249. [Google Scholar] [CrossRef] [PubMed]
  22. Gui, X.; Guzman, G.; Dobner, P.R.; Kadkol, S.S. Increased neurotensin receptor-1 expression during progression of colonic adenocarcinoma. Peptides. 2008, 29, 1609–1615. [Google Scholar] [CrossRef] [PubMed]
  23. Valerie, N.C.; Casarez, E.V.; Dasilva, J.O.; Dunlap-Brown, M.E.; Parsons, S.J.; Amorino, G.P.; Dziegielewski, J. Inhibition of neurotensin receptor 1 selectively sensitizes prostate cancer to ionizing radiation. Cancer Res. 2011, 71, 6817–6826. [Google Scholar] [CrossRef] [PubMed]
  24. Agopiantz, M.; Forgez, P.; Casse, J.M.; Lacomme, S.; Charra-Brunaud, C.; Clerc-Urmès, I.; Morel, O.; Bonnet, C.; Guéant, J.L.; Vignaud, J.M.; Gompel, A.; Gauchotte, G. Expression of neurotensin receptor 1 in endometrial adenocarcinoma is correlated with histological grade and clinical outcome. Virchows Arch. 2017, 471, 521–530. [Google Scholar] [CrossRef] [PubMed]
  25. Liu, J.; Agopiantz, M.; Poupon, J.; Wu, Z.; Just, P.A.; Borghese, B.; Ségal-Bendirdjian, E.; Gauchotte, G.; Gompel, A.; Forgez, P. Neurotensin Receptor 1 Antagonist SR48692 Improves Response to Carboplatin by Enhancing Apoptosis and Inhibiting Drug Efflux in Ovarian Cancer. Clin Cancer Res. 2017, 23, 6516–6528. [Google Scholar] [CrossRef]
  26. Sotiriou, C.; Wirapati, P.; Loi, S.; Harris, A.; Fox, S.; Smeds, J.; Nordgren, H.; Farmer, P.; Praz, V.; Haibe-Kains, B.; et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst. 2006, 98, 262–272. [Google Scholar] [CrossRef]
  27. Chin, K.; DeVries, S.; Fridlyand, J.; Spellman, P.T.; Roydasgupta, R.; Kuo, W.L.; Lapuk, A.; Neve, R.M.; Qian, Z.; Ryder, T.; et al. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell. 2006, 10, 529–541. [Google Scholar] [CrossRef]
  28. Tsuneoka, Y.; Yoshida, S.; Takase, K.; Oda, S.; Kuroda, M.; Funato, H. Neurotransmitters and neuropeptides in gonadal steroid receptor-expressing cells in medial preoptic area subregions of the male mouse. Sci Rep. 2017, 7, 9809. [Google Scholar] [CrossRef]
  29. Alexander, M.J.; Leeman, S.E. Estrogen-inducible neurotensin immunoreactivity in the preoptic area of the female rat. J Comp Neurol. 1994, 345, 496–509. [Google Scholar] [CrossRef]
  30. Tumurbaatar, T.; Kanasaki, H.; Oride, A.; Hara, T.; Okada, H.; Tsutsui, K.; Kyo, S. Action of neurotensin, corticotropin-releasing hormone, and RFamide-related peptide-3 in E2-induced negative feedback control: studies using a mouse arcuate nucleus hypothalamic cell model. Biol Reprod. 2018, 99, 1216–1226. [Google Scholar] [CrossRef]
  31. Arbogast, P.; Gauchotte, G.; Mougel, R.; Morel, O.; Ziyyat, A.; Agopiantz, M. Neurotensin and Its Involvement in Reproductive Functions: An Exhaustive Review of the Literature. Int J Mol Sci. 2023, 24, 4594. [Google Scholar] [CrossRef] [PubMed]
  32. Somaï, S.; Gompel, A.; Rostène, W.; Forgez, P. Neurotensin counteracts apoptosis in breast cancer cells. Biochem Biophys Res Commun. 2002, 295, 482–488. [Google Scholar] [CrossRef] [PubMed]
  33. Bodin, S.; Previti, S.; Jestin, E.; Vimont, D.; Ait-Arsa, I.; Lamare, F.; Rémond, E.; Hindié, E.; Cavelier, F.; Morgat, C. Design, Synthesis, and Biological Evaluation of the First Radio-Metalated Neurotensin Analogue Targeting Neurotensin Receptor 2. ACS Omega. 2023, 8, 6994–7004. [Google Scholar] [CrossRef] [PubMed]
  34. Castillo-Rodríguez, R.A.; Arango-Rodríguez, M.L.; Escobedo, L.; Hernandez-Baltazar, D.; Gompel, A.; Forgez, P.; Martínez-Fong, D. Suicide HSVtk gene delivery by neurotensin-polyplex nanoparticles via the bloodstream and GCV Treatment specifically inhibit the growth of human MDA-MB-231 triple negative breast cancer tumors xenografted in athymic mice. PLoS One. 2014, 9, e97151. [Google Scholar] [CrossRef]
  35. Currie, J.C.; Demeule, M.; Charfi, C.; Zgheib, A.; Larocque, A.; Danalache, B.A.; Ouanouki, A.; Béliveau, R.; Marsolais, C.; Annabi, B. The Peptide-Drug Conjugate TH1902: A New Sortilin Receptor-Mediated Cancer Therapeutic against Ovarian and Endometrial Cancers. Cancers (Basel). 2022, 14, 1877. [Google Scholar] [CrossRef]
  36. Demeule, M.; Charfi, C.; Currie, J.C.; Larocque, A.; Zgheib, A.; Kozelko, S.; Béliveau, R.; Marsolais, C.; Annabi, B. TH1902, a new docetaxel-peptide conjugate for the treatment of sortilin-positive triple-negative breast cancer. Cancer Sci. 2021, 112, 4317–4334. [Google Scholar] [CrossRef]
  37. Roselli, S.; Pundavela, J.; Demont, Y.; Faulkner, S.; Keene, S.; Attia, J.; Jiang, C.C.; Zhang, X.D.; Walker, M.M.; Hondermarck, H. Sortilin is associated with breast cancer aggressiveness and contributes to tumor cell adhesion and invasion. Oncotarget. 2015, 6, 10473–10486. [Google Scholar] [CrossRef]
  38. Hemmati, S.; Zarnani, A.H.; Mahmoudi, A.R.; Sadeghi, M.R.; Soltanghoraee, H.; Akhondi, M.M.; Tarahomi, M.; Jeddi-Tehrani, M.; Rabbani, H. Ectopic Expression of Sortilin 1 (NTR-3) in Patients with Ovarian Carcinoma. Avicenna J Med Biotechnol. 2009, 1, 125–131. [Google Scholar]
  39. Ghaemimanesh, F.; Ahmadian, G.; Talebi, S.; Zarnani, A.H.; Behmanesh, M.; Hemmati, S.; Hadavi, R.; Jeddi-Tehrani, M.; Farzi, M.; Akhondi, M.M.; Rabbani, H. The effect of sortilin silencing on ovarian carcinoma cells. Avicenna J Med Biotechnol. 2014, 6, 169–177. [Google Scholar]
  40. Sakumoto, R.; Hayashi, K.G.; Saito, S.; Kanahara, H.; Kizaki, K.; Iga, K. Comparison of the global gene expression profiles in the bovine endometrium between summer and autumn. J Reprod Dev. 2015, 61, 297–303. [Google Scholar] [CrossRef]
  41. Zhang, L.; Liu, X.; Che, S.; Cui, J.; Ma, X.; An, X.; Cao, B.; Song, Y. Endometrial Epithelial Cell Apoptosis Is Inhibited by a ciR8073-miR181a-Neurotensis Pathway during Embryo Implantation. Mol Ther Nucleic Acids. 2019, 14, 262–273. [Google Scholar] [CrossRef] [PubMed]
  42. Guha, S.; Rey, O.; Rozengurt, E. Neurotensin induces protein kinase C-dependent protein kinase D activation and DNA synthesis in human pancreatic carcinoma cell line PANC-1. Cancer Res. 2002, 62, 1632–1640. [Google Scholar] [PubMed]
  43. Seethalakshmi, L.; Mitra, S.P.; Dobner, P.R.; Menon, M.; Carraway, R.E. Neurotensin receptor expression in prostate cancer cell line and growth effect of NT at physiological concentrations. Prostate. 1997, 31, 183–192. [Google Scholar] [CrossRef]
  44. Shimizu, S.; Tsukada, J.; Sugimoto, T.; Kikkawa, N.; Sasaki, K.; Chazono, H.; Hanazawa, T.; Okamoto, Y.; Seki, N. Identification of a novel therapeutic target for head and neck squamous cell carcinomas: a role for the neurotensin-neurotensin receptor 1 oncogenic signaling pathway. Int J Cancer. 2008, 123, 1816–1823. [Google Scholar] [CrossRef]
  45. Wang, X.; Wang, Q.; Ives, K.L.; Evers, B.M. Curcumin inhibits neurotensin-mediated interleukin-8 production and migration of HCT116 human colon cancer cells. Clin Cancer Res. 2006, 12, 5346–5355. [Google Scholar] [CrossRef]
  46. Mijatovic, T.; Gailly, P.; Mathieu, V.; De Nève, N.; Yeaton, P.; Kiss, R.; DecaesteckerC. Neurotensin is a versatile modulator of in vitro human pancreatic ductal adenocarcinoma cell (PDAC) migration. Cell Oncol. 2007, 29, 315–326. [Google Scholar] [CrossRef]
  47. Ushiro, S.; Mizoguchi, K.; Yoshida, S.; Jimi, S.; Fujiwara, T.; Yoshida, M.; Wei, E.T.; Kitabgi, P.; Amagaya, S.; Ono, M.; Kuwano, M. Stimulation of cell-surface urokinase-type plasminogen activator activity and cell migration in vascular endothelial cells by a novel hexapeptide analogue of neurotensin. FEBS Lett. 1997, 418, 341–345. [Google Scholar] [CrossRef]
  48. Tang, K.H.; Ma, S.; Lee, T.K.; Chan, Y.P.; Kwan, P.S.; Tong, C.M.; Ng, I.O.; Man, K.; To, K.F.; Lai, P.B.; et al. CD133(+) liver tumor-initiating cells promote tumor angiogenesis, growth, and self-renewal through neurotensin/interleukin-8/CXCL1 signaling. Hepatology. 2012, 55, 807–820. [Google Scholar] [CrossRef]
  49. Ye, S.; Wang, B.; Zhou, Y.; Sun, Q.; Yang, X. Sortilin 1 regulates hepatocellular carcinoma progression by activating the PI3K/AKT signaling. Hum Exp Toxicol, 9: 41, 9603. [Google Scholar] [CrossRef]
  50. Gao, F.; Griffin, N.; Faulkner, S.; Li, X.; King, S.J.; Jobling, P.; Denham, J.W.; Jiang, C.C.; Hondermarck, H. The Membrane Protein Sortilin Can Be Targeted to Inhibit Pancreatic Cancer Cell Invasion. Am J Pathol. 2020, 190, 1931–1942. [Google Scholar] [CrossRef]
  51. Charfi, C.; Demeule, M.; Currie, J.C.; Larocque, A.; Zgheib, A.; Danalache, B.A.; Ouanouki, A.; Béliveau, R.; Marsolais, C.; Annabi, B. New Peptide-Drug Conjugates for Precise Targeting of SORT1-Mediated Vasculogenic Mimicry in the Tumor Microenvironment of TNBC-Derived MDA-MB-231 Breast and Ovarian ES-2 Clear Cell Carcinoma Cells. Front Oncol, 7: 11, 7607. [Google Scholar] [CrossRef]
  52. Ghaemimanesh, F.; Mehravar, M.; Milani, S.; Poursani, E.M.; Saliminejad, K. The multifaceted role of sortilin/neurotensin receptor 3 in human cancer development. J Cell Physiol. 2021, 236, 6271–6281. [Google Scholar] [CrossRef]
  53. Heakal, Y.; Kester, M. Nanoliposomal short-chain ceramide inhibits agonist-dependent translocation of neurotensin receptor 1 to structured membrane microdomains in breast cancer cells. Mol Cancer Res. 2009, 7, 724–734. [Google Scholar] [CrossRef] [PubMed]
  54. Dupouy, S.; Doan, V.K.; Wu, Z.; Mourra, N.; Liu, J.; De Wever, O.; Llorca, F.P.; Cayre, A.; Kouchkar, A.; Gompel, A.; Forgez, P. Activation of EGFR, HER2 and HER3 by neurotensin/neurotensin receptor 1 renders breast tumors aggressive yet highly responsive to lapatinib and metformin in mice. Oncotarget. 2014, 5, 8235–8251. [Google Scholar] [CrossRef]
  55. Norris, E.J.; Zhang, Q.; Jones, W.D.; DeStephanis, D.; Sutker, A.P.; Livasy, C.A.; Ganapathi, R.N.; Tait, D.L.; Ganapathi, M.K. Increased expression of neurotensin in high grade serous ovarian carcinoma with evidence of serous tubal intraepithelial carcinoma. J Pathol. 2019, 248, 352–362. [Google Scholar] [CrossRef] [PubMed]
  56. Martin, S.; Navarro, V.; Vincent, J.P.; Mazella, J. Neurotensin receptor-1 and -3 complex modulates the cellular signaling of neurotensin in the HT29 cell line. Gastroenterology. 2002, 123, 1135–1143. [Google Scholar] [CrossRef]
  57. Han, G.H.; Shim, J.E.; Yun, H.; Kim, J.; Kim, J.H.; Cho, H. RNA sequencing and bioinformatics analysis revealed PACSIN3 as a potential novel biomarker for platinum resistance in epithelial ovarian cancer. J Gene Med. 2022, 24, e3452. [Google Scholar] [CrossRef]
  58. Deng, H.; Wang, H.; Zhang, H.; Wang, M.; Giglio, B.; Ma, X.; Jiang, G.; Yuan, H.; Wu, Z.; Li, Z. Imaging Neurotensin Receptor in Prostate Cancer With 64Cu-Labeled Neurotensin Analogs. Mol Imaging, 1177. [Google Scholar] [CrossRef]
  59. Chilug, L.E.; Niculae, D.; Leonte, R.A.; Nan, A.; Turcu, R.; Mustaciosu, C.; Serban, R.M.; Lavric, V.; Manda, G. Preclinical Evaluation of NHS-Activated Gold Nanoparticles Functionalized with Bombesin or Neurotensin-Like Peptides for Targeting Colon and Prostate Tumours. Molecules. 2020, 25, 3363. [Google Scholar] [CrossRef]
  60. He, T.; Wang, M.; Wang, H.; Tan, H.; Tang, Y.; Smith, E.; Wu, Z.; Liao, W.; Hu, S.; Li, Z. Evaluation of neurotensin receptor 1 as potential biomarker for prostate cancer theranostic use. Eur J Nucl Med Mol Imaging. 2019, 46, 2199–2207. [Google Scholar] [CrossRef]
  61. Schollhammer, R.; Quintyn Ranty, M.L.; de Clermont Gallerande, H.; Cavelier, F.; Valverde, I.E.; Vimont, D.; Hindié, E.; Morgat, C. Theranostics of Primary Prostate Cancer: Beyond PSMA and GRP-R. Cancers (Basel). 2023, 15, 2345. [Google Scholar] [CrossRef] [PubMed]
  62. Zhang-Yin, J.; Provost, C.; Cancel-Tassin, G.; Rusu, T.; Penent, M.; Radulescu, C.; Comperat, E.; Cussenot, O.; Montravers, F.; Renard-Penna, R.; Talbot, J.N.; Prignon, A. A comparative study of peptide-based imaging agents [68Ga]Ga-PSMA-11, [68Ga]Ga-AMBA, [68Ga]Ga-NODAGA-RGD and [68Ga]Ga-DOTA-NT-20.3 in preclinical prostate tumour models. Nucl Med Biol 2020, 84-85, 88–95. [Google Scholar] [CrossRef]
  63. Wu, W.; Yu, F.; Zhang, P.; Bu, T.; Fu, J.; Ai, S.; You, Q.; Shi, L.; Shao, G.; Wang, F.; Hodolic, M.; Guo, H. 68Ga-DOTA-NT-20.3 Neurotensin Receptor 1 PET Imaging as a Surrogate for Neuroendocrine Differentiation of Prostate Cancer. J Nucl Med. 2022, 63, 1394–1400. [Google Scholar] [CrossRef]
  64. Hodolic, M.; Wu, W.Y.; Zhao, Z.; Yu, F.; Virgolini, I.; Wang, F. Safety and tolerability of 68Ga-NT-20.3, a radiopharmaceutical for targeting neurotensin receptors, in patients with pancreatic ductal adenocarcinoma: the first in-human use. Eur J Nucl Med Mol Imaging. 2021, 48, 1229–1234. [Google Scholar] [CrossRef] [PubMed]
  65. Maschauer, S.; Greff, C.; Einsiedel, J.; Ott, J.; Tripal, P.; Hübner, H.; Gmeiner, P.; Prante, O. Improved radiosynthesis and preliminary in vivo evaluation of a (18)F-labeled glycopeptide-peptoid hybrid for PET imaging of neurotensin receptor 2. Bioorg Med Chem. 2015, 23, 4026–4033. [Google Scholar] [CrossRef] [PubMed]
  66. Ma, X.; Wang, M.; Wang, H.; Zhang, T.; Wu, Z.; Sutton, M.V.; Popik, V.V.; Jiang, G.; Li, Z. Development of Bispecific NT-PSMA Heterodimer for Prostate Cancer Imaging: A Potential Approach to Address Tumor Heterogeneity. Bioconjug Chem. 2019, 30, 1314–1322. [Google Scholar] [CrossRef]
  67. Aoun, F.; Kourie, H.R.; Artigas, C.; Roumeguère, T. Next revolution in molecular theranostics: personalized medicine for urologic cancers. Future Oncol. 2015, 11, 2205–2219. [Google Scholar] [CrossRef] [PubMed]
  68. Schulz, J.; Rohracker, M.; Stiebler, M.; Goldschmidt, J.; Stöber, F.; Noriega, M.; Pethe, A.; Lukas, M.; Osterkamp, F.; Reineke, U.; Höhne, A.; Smerling, C.; Amthauer, H. Proof of Therapeutic Efficacy of a 177Lu-Labeled Neurotensin Receptor 1 Antagonist in a Colon Carcinoma Xenograft Model. J Nucl Med 2017, 58, 936–941. [Google Scholar] [CrossRef]
  69. Baxendale, I.R.; Cheung, S.; Kitching, M.O.; Ley, S.V.; Shearman, J.W. The synthesis of neurotensin antagonist SR 48692 for prostate cancer research. Bioorg Med Chem. 2013, 21, 4378–4387. [Google Scholar] [CrossRef]
  70. Zhu, S.; Tian, H.; Niu, X.; Wang, J.; Li, X.; Jiang, N.; Wen, S.; Chen, X.; Ren, S.; Xu, C.; Chang, C.; Flores-Morales, A.; Shang, Z.; Sun, Y.; Niu, Y. Neurotensin and its receptors mediate neuroendocrine transdifferentiation in prostate cancer. Oncogene. 2019, 38, 4875–4884, 10.1038/s41388-019-0750-5. Epub 2019 Feb 15. Erratum in: Oncogene. 2019 Jun;38, 4885. [Google Scholar] [CrossRef]
  71. Valerie, N.C.; Casarez, E.V.; Dasilva, J.O.; Dunlap-Brown, M.E.; Parsons, S.J.; Amorino, G.P.; Dziegielewski, J. Inhibition of neurotensin receptor 1 selectively sensitizes prostate cancer to ionizing radiation. Cancer Res. 2011, 71, 6817–6826. [Google Scholar] [CrossRef]
  72. Falciani, C.; Lelli, B.; Brunetti, J.; Pileri, S.; Cappelli, A.; Pini, A.; Pagliuca, C.; Ravenni, N.; Bencini, L.; Menichetti, S.; Moretti, R.; De Prizio, M.; Scatizzi, M.; Bracci, L. Modular branched neurotensin peptides for tumor target tracing and receptor-mediated therapy: a proof-of-concept. Curr Cancer Drug Targets. 2010, 10, 695–704. [Google Scholar] [CrossRef]
  73. Falciani, C.; Brunetti, J.; Pagliuca, C.; Menichetti, S.; Vitellozzi, L.; Lelli, B.; Pini, A.; Bracci, L. Design and in vitro evaluation of branched peptide conjugates: turning nonspecific cytotoxic drugs into tumor-selective agents. ChemMedChem. 2010, 5, 567–574. [Google Scholar] [CrossRef]
  74. HHe, X.; Cai, K.; Zhang, Y.; Lu, Y.; Guo, Q.; Zhang, Y.; Liu, L.; Ruan, C.; Chen, Q.; Chen, X.; Li, C.; Sun, T.; Cheng, J.; Jiang, C. Dimeric Prodrug Self-Delivery Nanoparticles with Enhanced Drug Loading and Bioreduction Responsiveness for Targeted Cancer Therapy. ACS Appl Mater Interfaces. 2018, 10, 39455–39467. [Google Scholar] [CrossRef] [PubMed]
  75. Demeule, M.; Charfi, C.; Currie, J.C.; Larocque, A.; Zgheib, A.; Kozelko, S.; Béliveau, R.; Marsolais, C.; Annabi, B. TH1902, a new docetaxel-peptide conjugate for the treatment of sortilin-positive triple-negative breast cancer. Cancer Sci. 2021, 112, 4317–4334. [Google Scholar] [CrossRef] [PubMed]
  76. Wu, Z.; Fournel, L.; Stadler, N.; Liu, J.; Boullier, A.; Hoyeau, N.; Fléjou, J.F.; Duchatelle, V.; Djebrani-Oussedik, N.; Agopiantz, M.; Ségal-Bendirdjian, E.; Gompel, A.; Alifano, M.; Melander, O.; Trédaniel, J.; Forgez, P. Modulation of lung cancer cell plasticity and heterogeneity with the restoration of cisplatin sensitivity by neurotensin antibody. Cancer Lett 2019, 444, 147–161. [Google Scholar] [CrossRef] [PubMed]
  77. Zhuang, W.; Zhang, W.; Xie, L.; Wang, L.; Li, Y.; Wang, Z.; Zhang, A.; Qiu, H.; Feng, J.; Zhang, B.; Hu, Y. Generation and Characterization of SORT1-Targeted Antibody-Drug Conjugate for the Treatment of SORT1-Positive Breast Tumor. Int J Mol Sci. 2023, 24, 17631. [Google Scholar] [CrossRef]
Preprints 119340 g001
Figure 1. Synthesis of roles and perspectives for NT and its receptors in breast, ovarian and endometrial cancers. NT: neurotensin, NTR1: neurotensin receptor 1, NTR2: neurotensin receptor 2, SORT1: sortilin.
Figure 1. Synthesis of roles and perspectives for NT and its receptors in breast, ovarian and endometrial cancers. NT: neurotensin, NTR1: neurotensin receptor 1, NTR2: neurotensin receptor 2, SORT1: sortilin.
Preprints 119340 g001
Table 1. Expression of NT and its receptors in female hormone sensitive cancers.
Table 1. Expression of NT and its receptors in female hormone sensitive cancers.
Tissues Type of sample NT NTR1 NTR2 SORT1 References
Breast Human breast adenocarcinoma
Human normal breast tissue
MCF-7 (human ER-positive breast cancer CL)		 +/+++
-/+
NA 		+/+++
-
+++		 NA
NA
+		 +/+++
-
+++		 [19,21,36,37]
[19,21,37]
[21,32,33,37]
MDA-MB-231 (human triple negative breast cancer CL) NA +++ - +++ [21,33,37]
Ovary


 Human ovarian adenocarcinoma
Human normal ovarian tissue
SKOV3 (human epithelial ovarian cancer CL)		 +
+
+
 +/+++
-
+++
 NA
NA
-
 +++
-
+++
 [25,35,38]
[25,35,38]
[25,35,38]
Endometrium Human adenocarcinoma
Human normal endometrium
HEC-1-A & HEC-1-B (human endometrial cancer CL)		 +++
-
NA
 +/+++
-
NA
 NA
NA
NA		 +/+++
-
+
 [24,35]
[24,35]
[35]
CL: cell line, ER: estrogen receptor, NA: not available, NT: neurotensin, NTR1: neurotensin receptor 1, NTR2: neurotensin receptor 2, SORT1: sortilin, -: no expression, +: weak expression, +++: strong expression.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.
Prerpints.org logo

Preprints.org is a free preprint server supported by MDPI in Basel, Switzerland.

facebook logotwitter logolinkedin logo
MDPI Initiatives
Important Links
Subscribe

Disclaimer

Terms of Use

Privacy Policy

© 2024 MDPI (Basel, Switzerland) unless otherwise stated